TP53 and B-cell chronic lymphocytic leukemia: From the perspective of Chinese payer, IB as a first-line treatment strategy is more cost-effective than the BE plus RI strategy for the treatment of older patients with previously untreated CLL not harboring the del(17p)/TP53 mutation.